Daiichi Sankyo
Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) is a holding corporation that conducts pharmaceutical research, development, manufacturing, and marketing. The company provides a comprehensive range of prescription medications, over-the-counter (OTC) pharmaceuticals, vaccines, and other products. Its product range includes medications for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious disorders, as well as many types of cancer. Aside from cancer, the company's other research interests include uncommon diseases and immunological disorders.
Daiichi Sankyo's products are sold through its group companies and a large network of medical representatives. Its operations are spread over North America, South and Central America, Europe, and Asia. Daiichi Sankyo is based in Tokyo, Japan. The company owns Plexxikon in the United States, American Regent in the United States, U3 Pharma in Germany, and Ranbaxy Laboratories in India, which it just sold. Benicar (Olmesartan), an angiotensin II receptor antagonist and top-selling medicine in the United States, is manufactured by Daiichi Sankyo Co., Ltd. Olmesartan had global sales of 300.2 billion JPY in 2013.
Founded: 2005
Headquarters: Tokyo, Japan
Official website: https://www.daiichisankyo.com/
